Alt Biotech automates the production of non-therapeutic recombinant proteins using advanced bioproduction techniques. This approach addresses the inefficiencies in traditional protein production methods, enabling faster and more cost-effective solutions for research and industrial applications.
Funding
$260K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional methods of producing non-therapeutic recombinant proteins are often inefficient, time-consuming, and costly, hindering research and industrial applications that rely on these proteins. These inefficiencies can slow down innovation and increase the overall cost of development in various fields.
Solution
Alt Biotech automates the production of non-therapeutic recombinant proteins using advanced bioproduction techniques. This automated approach streamlines the protein production process, resulting in faster turnaround times and reduced costs compared to traditional methods. By optimizing the bioproduction process, Alt Biotech enables researchers and industrial users to access high-quality recombinant proteins more efficiently and affordably. This facilitates quicker experimentation, faster product development, and overall advancements in related fields.
Target Audience
Alt Biotech's primary customers are researchers and industrial users who require non-therapeutic recombinant proteins for their work.
Features
- Automated bioproduction system for recombinant proteins
- Streamlined production process for faster turnaround times
- Cost-effective protein production solutions
- High-quality recombinant proteins for research and industrial applications